CO5700743A2 - Formas polimorficas de un agonista de gaba a - Google Patents
Formas polimorficas de un agonista de gaba aInfo
- Publication number
- CO5700743A2 CO5700743A2 CO06073254A CO06073254A CO5700743A2 CO 5700743 A2 CO5700743 A2 CO 5700743A2 CO 06073254 A CO06073254 A CO 06073254A CO 06073254 A CO06073254 A CO 06073254A CO 5700743 A2 CO5700743 A2 CO 5700743A2
- Authority
- CO
- Colombia
- Prior art keywords
- peak
- powder
- values
- ray diffraction
- cuka radiation
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 229910016523 CuKa Inorganic materials 0.000 abstract 6
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 6
- 230000005855 radiation Effects 0.000 abstract 6
- 238000001228 spectrum Methods 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 229950004346 gaboxadol Drugs 0.000 abstract 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 abstract 1
- UDHPXYNRXFPDOF-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-6-ium-3-olate;hydrate Chemical compound O.C1NCCC2=C1ON=C2O UDHPXYNRXFPDOF-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- -1 gaboxadol monohydrate compound Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402118.4A GB0402118D0 (en) | 2004-01-30 | 2004-01-30 | Polymorphic forms of a GABAA agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5700743A2 true CO5700743A2 (es) | 2006-11-30 |
Family
ID=31971783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO06073254A CO5700743A2 (es) | 2004-01-30 | 2006-07-26 | Formas polimorficas de un agonista de gaba a |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US7262300B2 (https=) |
| EP (2) | EP1713813B1 (https=) |
| JP (1) | JP4917440B2 (https=) |
| KR (1) | KR101210361B1 (https=) |
| CN (1) | CN1914212B (https=) |
| AR (1) | AR047511A1 (https=) |
| AT (1) | ATE414088T1 (https=) |
| AU (1) | AU2005209473B2 (https=) |
| BR (1) | BRPI0506858A (https=) |
| CA (1) | CA2554536C (https=) |
| CO (1) | CO5700743A2 (https=) |
| CY (1) | CY1108647T1 (https=) |
| DE (1) | DE602005010975D1 (https=) |
| DK (1) | DK1713813T3 (https=) |
| DO (1) | DOP2005000013A (https=) |
| EA (1) | EA009413B1 (https=) |
| EC (1) | ECSP066735A (https=) |
| ES (1) | ES2314613T3 (https=) |
| GB (2) | GB0402118D0 (https=) |
| HR (1) | HRP20080614T3 (https=) |
| IL (1) | IL176863A0 (https=) |
| MA (1) | MA28364A1 (https=) |
| MX (1) | MXPA06008595A (https=) |
| MY (1) | MY139525A (https=) |
| NO (1) | NO20063843L (https=) |
| NZ (1) | NZ548191A (https=) |
| PE (1) | PE20050769A1 (https=) |
| PL (1) | PL1713813T3 (https=) |
| PT (1) | PT1713813E (https=) |
| SI (1) | SI1713813T1 (https=) |
| TW (1) | TWI345972B (https=) |
| UA (1) | UA87487C2 (https=) |
| WO (1) | WO2005073237A2 (https=) |
| ZA (1) | ZA200605307B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US8268866B2 (en) | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US9072662B2 (en) | 2004-03-29 | 2015-07-07 | Auris Medical Ag | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| DE102005004343A1 (de) * | 2005-01-25 | 2006-08-10 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung von Phantomphänomenen |
| WO2006083682A2 (en) * | 2005-01-28 | 2006-08-10 | H.Lundbeck A/S | Polymorphic forms of a gabaa agonist |
| ES2524994T3 (es) | 2005-09-28 | 2014-12-16 | Auris Medical Ag | Composiciones farmacéuticas para el tratamiento de trastornos del oído interno. |
| CN102093387B (zh) * | 2009-12-10 | 2012-07-25 | 天津泰普医药知识产权流转储备中心有限公司 | 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物 |
| EP2790686B1 (en) | 2011-12-12 | 2021-03-10 | Zilentin Ag | Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system |
| IL256912B2 (en) | 2015-07-17 | 2024-01-01 | Ovid Therapeutics Inc | Methods of treating developmental disorders with gaboxadol |
| EP4233861A3 (en) | 2016-08-11 | 2023-10-11 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
| EP3528807A4 (en) * | 2016-11-22 | 2020-06-17 | Ovid Therapeutics Inc | METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN |
| US10071083B2 (en) * | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| JP2020529440A (ja) | 2017-08-04 | 2020-10-08 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 糖尿病および関連する状態の処置におけるガボキサドールの使用 |
| MX2021003302A (es) | 2018-09-20 | 2021-05-13 | Ovid Therapeutics Inc | Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez. |
| US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| EP3880201A4 (en) | 2018-12-17 | 2022-07-27 | Ovid Therapeutics Inc. | USE OF GABOXADOL IN THE TREATMENT OF NON-24 HOUR SLEEP waking disorder |
| EP4051272A4 (en) | 2019-12-18 | 2023-01-04 | Ovid Therapeutics Inc. | GABOXADOL FOR THE THERAPEUTIC TREATMENT OF 1P36 DELETION SYNDROME |
| MX2022014599A (es) | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270278A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Cycliske aminosyrer |
| US4315934A (en) | 1979-09-24 | 1982-02-16 | Sandoz Ltd. | Organic compounds |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4352731A (en) * | 1980-11-03 | 1982-10-05 | Occidental Research Corporation | Apparatus for selective wetting of particles |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| UA52661C2 (uk) * | 1996-06-14 | 2003-01-15 | Ново Нордіск А/С | Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти |
| EP1220658A1 (en) | 1999-09-28 | 2002-07-10 | H. Lundbeck A/S | Melt granulated composition and modified release dosage form prepared from said composition |
| AR031473A1 (es) | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
| CA2447417C (en) | 2001-05-18 | 2011-10-04 | Lonza Ag | Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate |
| CN1511026A (zh) | 2001-05-21 | 2004-07-07 | H��¡�±�������˾ | 加波沙朵颗粒制剂 |
| CN100491366C (zh) * | 2002-09-03 | 2009-05-27 | 华晶基因技术有限公司 | 汉黄芩素用作治疗焦虑症的药物的用途 |
| US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| DK1641456T3 (da) * | 2003-06-25 | 2010-06-21 | Lundbeck & Co As H | Gaboxadol til behandling af depression og andre affektive lidelser |
| AR045540A1 (es) | 2003-09-05 | 2005-11-02 | Lundbeck & Co As H | Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip) |
| US20070032553A1 (en) | 2003-09-10 | 2007-02-08 | Mckernan Ruth | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
| TW200528098A (en) | 2003-12-18 | 2005-09-01 | Lundbeck & Co As H | Treatment of insomnia in human patients |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| JP2008504306A (ja) | 2004-06-29 | 2008-02-14 | ハー・ルンドベック・アクチエゼルスカベット | 神経因性疼痛、線維筋痛症または慢性関節リウマチの治療 |
| GB0417558D0 (en) | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| WO2006083682A2 (en) | 2005-01-28 | 2006-08-10 | H.Lundbeck A/S | Polymorphic forms of a gabaa agonist |
| WO2006102093A1 (en) | 2005-03-18 | 2006-09-28 | Transform Pharmaceuticals, Inc. | Gaboxadol forms, compositions thereof, and related methods |
| US20080262029A1 (en) | 2005-04-29 | 2008-10-23 | H. Lundbeck A/S | Acid and Base Salt Forms of Gaboxadol |
-
2004
- 2004-01-30 GB GBGB0402118.4A patent/GB0402118D0/en not_active Ceased
-
2005
- 2005-01-20 AR ARP050100210A patent/AR047511A1/es not_active Application Discontinuation
- 2005-01-21 TW TW094101857A patent/TWI345972B/zh not_active IP Right Cessation
- 2005-01-24 MY MYPI20050253A patent/MY139525A/en unknown
- 2005-01-27 PE PE2005000102A patent/PE20050769A1/es not_active Application Discontinuation
- 2005-01-28 US US11/045,768 patent/US7262300B2/en not_active Expired - Lifetime
- 2005-01-28 WO PCT/GB2005/000288 patent/WO2005073237A2/en not_active Ceased
- 2005-01-28 PL PL05702040T patent/PL1713813T3/pl unknown
- 2005-01-28 DE DE602005010975T patent/DE602005010975D1/de not_active Expired - Lifetime
- 2005-01-28 GB GB0501847A patent/GB2410434A/en not_active Withdrawn
- 2005-01-28 EA EA200601404A patent/EA009413B1/ru not_active IP Right Cessation
- 2005-01-28 JP JP2006550301A patent/JP4917440B2/ja not_active Expired - Lifetime
- 2005-01-28 CN CN2005800031615A patent/CN1914212B/zh not_active Expired - Lifetime
- 2005-01-28 ES ES05702040T patent/ES2314613T3/es not_active Expired - Lifetime
- 2005-01-28 UA UAA200609410A patent/UA87487C2/ru unknown
- 2005-01-28 NZ NZ548191A patent/NZ548191A/en not_active IP Right Cessation
- 2005-01-28 BR BRPI0506858-4A patent/BRPI0506858A/pt not_active IP Right Cessation
- 2005-01-28 DK DK05702040T patent/DK1713813T3/da active
- 2005-01-28 EP EP05702040A patent/EP1713813B1/en not_active Expired - Lifetime
- 2005-01-28 DO DO2005000013A patent/DOP2005000013A/es unknown
- 2005-01-28 AT AT05702040T patent/ATE414088T1/de active
- 2005-01-28 MX MXPA06008595A patent/MXPA06008595A/es active IP Right Grant
- 2005-01-28 SI SI200530521T patent/SI1713813T1/sl unknown
- 2005-01-28 CA CA2554536A patent/CA2554536C/en not_active Expired - Fee Related
- 2005-01-28 PT PT05702040T patent/PT1713813E/pt unknown
- 2005-01-28 HR HR20080614T patent/HRP20080614T3/xx unknown
- 2005-01-28 EP EP08019457A patent/EP2042505A1/en not_active Withdrawn
- 2005-01-28 AU AU2005209473A patent/AU2005209473B2/en not_active Ceased
-
2006
- 2006-06-27 ZA ZA200605307A patent/ZA200605307B/en unknown
- 2006-07-13 IL IL176863A patent/IL176863A0/en unknown
- 2006-07-26 CO CO06073254A patent/CO5700743A2/es not_active Application Discontinuation
- 2006-07-28 KR KR1020067015417A patent/KR101210361B1/ko not_active Expired - Fee Related
- 2006-07-28 EC EC2006006735A patent/ECSP066735A/es unknown
- 2006-08-22 MA MA29278A patent/MA28364A1/fr unknown
- 2006-08-29 NO NO20063843A patent/NO20063843L/no not_active Application Discontinuation
-
2007
- 2007-07-13 US US11/827,570 patent/US8236958B2/en active Active
-
2008
- 2008-12-10 CY CY20081101439T patent/CY1108647T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5700743A2 (es) | Formas polimorficas de un agonista de gaba a | |
| NO20080784L (no) | Histondeacetylaseinhibitorer | |
| AR074507A1 (es) | Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra. | |
| WO2007028135A3 (en) | Imidazopyridine compounds | |
| MY146989A (en) | Kinase inhibitors | |
| CO6321230A2 (es) | Compuesto espiro, una sal aceptable para uso farmaceutico y un solvato del mismo y composicion farmaceutica que lo contenga | |
| PA8660001A1 (es) | Amino-imidazolonas para la inhibicion de b-secretasa | |
| WO2006133147A3 (en) | Organic compounds | |
| CR9272A (es) | Amino-imidazolonas para la inhibicion de b-secretasa | |
| AR111812A2 (es) | Compuestos y composiciones para el control de nematodos | |
| CY1113011T1 (el) | Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην | |
| CL2008002703A1 (es) | Compuestos derivados de 1,4-dihidro-2h-piridazin-3-ona; composicion herbicida que comprende a dichos compuestos; metodo de control de malezas; uso de dichos compuestos para el control de malezas; y compuestos intermediarios. | |
| ATE479687T1 (de) | Kinaseinhibitoren | |
| TW200706636A (en) | Compounds for organic electronic devices | |
| TW200702421A (en) | Compounds for organic electronic devices | |
| WO2007078813A3 (en) | 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION | |
| GEP20115251B (en) | Smac peptidomimetics useful as iap inhibitors | |
| TW200613515A (en) | Compounds for organic electronic devices | |
| WO2008014319A3 (en) | Multi-dispersant lubricating composition | |
| GB0521508D0 (en) | Organic compounds | |
| GEP20125523B (en) | Metabolites of (thio) carbamoyl-cyclohexane derivatives | |
| MXPA05008367A (es) | Derivados de pirazol. | |
| EA200971080A1 (ru) | Кристаллическое соединение пиридазина | |
| MY185130A (en) | Romidepsin solid forms and uses thereof | |
| TW200721903A (en) | Organic electroluminescence device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |